Norgine's Strategic Acquisition of Theravia to Bolster Rare Disease Portfolio

Norgine acquires Theravia, adding rare disease treatments to its portfolio and strengthening its position in the European market.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here